共 50 条
Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): Just a coincidence?
被引:4
|作者:
Soubrier, Martin
[1
]
Haik, Stephane
[2
,3
]
Hauw, Jean-Jacques
[3
]
Corvol, Jean Christophe
Lyon-Caen, Olivier
Dougados, Maxime
[4
]
机构:
[1] Hop G Montpied, Serv Rhumatol, F-63003 Clermont Ferrand, France
[2] INSERM, Equipe Avenir Malad Prions Chez Homme, Paris, France
[3] Grp Hosp Pitie Salpetriere, AP HP, Lab Neuropathol Raymond Escourolle, F-75634 Paris, France
[4] Univ Paris 05, Hop Cochin, AP HP, Serv Rhumatol B, F-75679 Paris, France
关键词:
Rheumatoid arthritis;
Biologics;
TNF-blocker;
Creutzfeldt-Jacob disease;
CYTOKINES;
D O I:
10.1016/j.jbspin.2009.05.016
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
We describe a patient in whom sporadic Creutzfeldt-Jakob disease (sCJD) occured one year after the onset of etanercept therapy for rheumatoid arthritis (RA). This association could be a chance occurrence. However, TNF-alpha has been implicated in the pathogenesis of neurodegeneration in sCJD and etanercept might worsen the disease. Such an aggravation has been observed in multiple sclerosis, in which TNF-alpha is the key mediator of demyelination. It may be of interest studying the impact of treatment with TNF-alpha antagonists on prevalence and incidence of those neurodegenerative diseases involving TNF-alpha mediation, such as Alzheimer disease. (C) 2009 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.,
引用
收藏
页码:174 / 175
页数:2
相关论文